A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
- Substances:–
Italy- Participants:18–64 years
- Sponsor:Zenas Biopharma (USA) LLC
Rare diseases
Investigational molecules
Locations
Back to Italy45 clinical trials in Pozzilli, Italy. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in ItalyStudi-Clinici.it(opens in a new tab)
Italy
Italy
Italy
Italy
Italy
Italy
Italy
Italy
Italy
Italy
Italy
ItalyThe busiest research cities in the country
What the registry says about research in the country
Groundbreaking research focusing on Multiple Sclerosis treatments, including studies of new therapies like frexalimab, remibrutinib, and ocrelizumab. Investigations aim to improve treatment efficacy and develop innovative drug delivery methods.
Multiple ongoing trials evaluating both intravenous and subcutaneous administration methods for enhanced patient care.
Clinical research examining new therapeutic approaches for Parkinson's Disease, with particular attention to early-stage interventions and LRRK2-driven variants. Studies focus on novel compounds like NEU-411 and BIIB122.
Emphasis on safety evaluation and efficacy assessment of new therapeutic compounds.
Innovative studies targeting cardiovascular disease and related conditions, including trials of pelacarsen for lipoprotein management and inclisiran for preventing major cardiovascular events.
Focus on reducing cardiovascular events and improving outcomes in high-risk patients.
Research initiatives investigating treatments for sleep disorders and related neurological conditions, with studies evaluating TAK-861 for narcolepsy and new approaches for idiopathic hypersomnia.
Trials focused on improving daily functioning and quality of life for patients.
Studies addressing Alzheimer's Disease psychosis and related conditions, with trials evaluating ACP-204 for symptom management and long-term safety assessments.
Research aimed at developing effective treatments for psychiatric symptoms in neurodegenerative conditions.
Tell us about your condition – we search every trial in Europe and connect you with the right site.